New Clinical Trial Studies Metformin for Pseudomyxoma Peritonei (PMP)

ACPMP’s Clinical Trials Database is regularly updated with new research studies and trial opportunities for the appendix cancer and PMP community. One of our recent additions is a new metformin trial for PMP, led by Dr. Oliver Eng at the University of California, Irvine.

About the trial

The study is evaluating metformin – a medication commonly used to treat diabetes – in patients with pseudomyxoma peritonei (PMP) caused by appendiceal mucinous neoplasms. It is a small pilot study designed to see whether metformin therapy is feasible and well tolerated in this group of patients.

The trial is intended for patients with PMP who are not currently planned to undergo cytoreductive surgery and HIPEC (CRS/HIPEC), including:

• Patients whose disease has come back after prior CRS/HIPEC
• Patients whose disease cannot be removed with surgery

Building on earlier research

This clinical trial builds on prior laboratory research conducted by Dr. Eng and his team with support from ACPMP. That work explored how PMP tumors use energy and nutrients, suggesting they may respond to drugs that affect cell metabolism, such as metformin.

How to learn more

Trial ID: NCT07693452. View the full trial listing on ClinicalTrials.gov.

Patients interested in this study or other trials can visit ACPMP’s Clinical Trials Database and discuss potential eligibility with their healthcare provider.

This summary is for general information only and is not medical advice. Please talk with your care team about what this research may mean for you.